Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series.

ABSTRACT:

Objective

This real-world retrospective case series evaluates the safety and efficacy of aflibercept 8 mg in patients diagnosed with neovascular age-related macular degeneration (nAMD).

Methods and analyses

Treatment-naïve or treatment-experienced patients with nAMD receiving aflibercept 8 mg with at least 6 months of follow-up were assessed.

Results

40 eyes from 33 patients were included, of which 36/40 eyes were previously treated. The mean age of subjects is 79.84 years. At baseline, 29/36 eyes had intraretinal fluid (IRF)/subretinal fluid (SRF) at an average interval of 40.97 days, logMAR VA of 0.346, and average central subfield thickness (CST) of 341.53 µm. At final follow-up, average logMAR VA was 0.315 and average CST decreased by 39.39 µm, with an average num

SUBMITTER: Sambhara D 

PROVIDER: S-EPMC11831258 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature